Clinical trials: Multiple Sclerosis (MS) - Relapsing-remitting
Relapse Remitting Multiple Sclerosis
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
This study investigates the add-on effect of oral minocycline in subjects treated with daily injection of Copaxone. Copaxone and minocycline are thought to have differential modes of actions that may complement each other in…
- Trial name
- NCT00203112
- Testing
- glatiramer acetate with minocycline
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis (MS) - Relapsing-remitting
Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MS
To furnish behavioral and electrophysiological evidence of the possible modulation of fatigue in Multiple Sclerosis - relapsing remitting form, through a verbal placebo.
- Trial name
- Fatigue_SM (NCT07624812)
- Testing
- TENS therapy
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Auxologico Italiano
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
MS-ResearchBiomarkerS
This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MS-ReBS (NCT05204459)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Multiple Sclerosis
Cognitive Effects of Immunomodulatory Drugs in MS
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Trial name
- NCT00229502
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sharon Lynch, MD
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- DanNORMS (NCT04688788)
- Testing
- Rituximab, Ocrelizumab, Fexofenadine
- Where
- 11 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis, Relapsing-Remitting
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
The purpose of this study is to assess the impact of Natalizumab (Tysabri) therapy on sleep efficiency, total sleep time and sleep latency, in Multiple Sclerosis (MS) patients receiving Natalizumab for 6 months relative to…
- Trial name
- NCT01591551
- Testing
- Natalizumab (Tysabri)
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cornerstone Health Care, PA
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A on Multiple Sclerosis (MS)
The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for first 6 months and 10000 IU/day for next 6 months on disease activity and…
- Trial name
- MS (NCT01417273)
- Testing
- vitamin A
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
A randomized trial of long-term dosage of rituximab in multiple sclerosis
- Trial name
- RIDOSE-MS (NCT03979456)
- Testing
- Rituximab
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska Institutet
Relapsing-Remitting Multiple Sclerosis
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
This was an open-label, multicentric, prospective, post-marketing surveillance (PMS) study to investigate whether baseline treatment with high-dose interferon beta 1a (Rebif 44 μg x 3 ), administered at a high frequency, leads to…
- Trial name
- RETURN (NCT01142518)
- Testing
- Interferon beta 1a
- Volunteers
- 86 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
Development of a Motivational Intervention to Improve Treatment Adherence in MS
As many as 50% of MS patients prematurely discontinue their disease modifying medications. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled trial.
- Trial name
- MIMS (NCT01925690)
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy, Brief Education
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Missouri, Kansas City
Relapsing-remitting Multiple Sclerosis
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone.
- Trial name
- NCT00168766
- Testing
- Interferon-beta-1a (Avonex) plus methylprednisolone
- Where
- 9 sites in Belgium, Denmark and 6 more
- Volunteers
- 345 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis, Fatigue
Behavior Cognitive Therapy on Fatigue Impact in MS Patients
Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination of the central nervous system. Fatigue is one of the most frequent and most disabling symptoms of MS.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Cognitive Therapy
- Trial name
- NCT03758820
- Testing
- Behavorial Cognitive Therapy (BCT)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Réseau Sep Idf Ouest
Multiple Sclerosis, Relapsing-Remitting
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
- Trial name
- NCT00097760
- Testing
- Natalizumab
- Volunteers
- 110 people
- Sponsor
- Biogen
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period.
- Trial name
- PROTEC (NCT01930708)
- Testing
- dimethyl fumarate
- Where
- 90 sites in Austria, Belgium and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Biogen